Navigation Links
Pharmaceutical Market & Biotechnology Industry 2013 Outlook in New Research Reports at ReportsnReports.com
Date:2/8/2013

nd AZN May Have To Take Some Bold Initiatives
  • Eli Lilly: Late Stage Pipeline Fickle And Risky
  • Merck: News-flow from Mega-trial on MRK's cardiology Franchise would reshape Merck's Growth Prospects
  • Novartis: Back on a Growth Trajectory
  • Novo Nordisk: Hemophilia Franchise and Thrice Weekly Degludec – The Future Drivers
  • Pfizer: M&A Only Can Drive Further Upside In The Near Term
  • Sanofi: Solid Base Business, But Upside From Pipeline Will Take Longer To Come About
  • Global Pharma Sector Industry Tables
  • Profitable Biotech (Mature Biotech) and non-Profitable Biotech companies (Rising stars) have developed innovative drugs for treatment of chronic and non chronic diseases. In the next five years the distinction between mature biotech companies and large global pharma is likely to disappear as investment in R&D and acquisition start delivering and Market Cap match the large global pharma. Dividend and consolidation could be the future drivers and continue to attract long term investors. Optimism prevails around the future of this sector as a whole which was reflected in the unprecedented rally in shares in 2012. We expect this trend to continue in the next five year driven by launch of Innovative drugs catering to unmet needs in Alzheimer's, HCV, osteoporosis, RA, Psoriasis, MS, Dyslipidemia, Cystic fibrosis, Cancer and orphan diseases. Drug approvals and label expansion of existing portfolio of launched drugs and data from late stage pipeline drugs should maintain the growth momentum and investors interest.

    "Global Pharmaceutical & Biotechnology Outlook 2013: Mature Biotech" sector report provides valuations and an in depth analyses of biotech companies, their launched drug portfolio and promising drug candidates in the pipeline. The report disc
    '/>"/>

    SOURCE ReportsnReports.com
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Imprimis Pharmaceuticals Announces Pricing of Public Offering of 1,840,000 Shares of Common Stock
    2. Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference
    3. Avanir Pharmaceuticals Reports Fiscal 2013 First Quarter Financial And Business Results
    4. Ohr Pharmaceutical to Present at 15th Annual BIO CEO & Investor Conference
    5. Shares of Oramed Pharmaceuticals Are Approved for Listing on the Nasdaq Capital Market
    6. Pharmaceutical Pricing and Reimbursement in China - Series of Mandated Price Cuts Not Effective in Stemming Healthcare Expenditures
    7. Emerging Pharmaceutical Market in South Africa - Proposed Introduction of New Drug Regulatory Agency (SAHPRA) to Accelerate Drug Registration Process
    8. Avanir Pharmaceuticals Announces Positive Interim Data From Pharmacokinetic Study With Next Generation Compound AVP-786
    9. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Fiscal Year 2012 Financial Results
    10. Optimer Pharmaceuticals to Present at Leerink Swann Global Healthcare Conference
    11. KaloBios Pharmaceuticals Completes Initial Public Offering
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/22/2014)... -- Sanomedics International Holdings, Inc. (OTCQB: SIMH) – According ... Data Services, demand for thermometers is expected to grow ... demand for more accurate digital thermometers continues.  ... market for thermometers, and one of the companies serving ... Inc. Sanomedics International Holdings designs, develops, markets, ...
    (Date:10/22/2014)... Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes in ... drug for cancer, is designed for injection into solid ... oncology focus is on melanoma, breast cancer and cancers ... of PV-10 as a therapy for metastatic melanoma, and ... and psoriasis. This summer, the Company ...
    (Date:10/22/2014)... , Oct. 22, 2014  Regulus ... a biopharmaceutical company leading the discovery and ... announced that it has demonstrated human proof-of-concept ... clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated ... of hepatitis C virus infection ("HCV").  Interim ...
    Breaking Medicine Technology:Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
    (Date:10/22/2014)... Although there are only 24 hours in a day, ... have trouble finding time within their busy schedules for exercise and ... of time to get in shape. Here are five ways you ... , Change Up Your Commute , Consider riding a bike ... exercise into your daily routine. If you must use your car ...
    (Date:10/22/2014)... 2014 Akeso Biomedical, Inc. , ... treatment of bacterial infections, microbial biofilms, and chronic wounds, ... board of directors. , Dr. Sinskey ... The Massachusetts Institute of Technology, or MIT. He has ... Dr. Sinskey also holds positions as Co-Director of the ...
    (Date:10/22/2014)... Two sisters in high school have developed ways to ... Krishen use electronic stethoscopes, which electronically amplify body sounds, ... or heartbeats. Ilina, a senior at Port Huron ... way to detect early lung damage in people exposed ... recorded one breath cycle each from 16 smokers, 25 ...
    (Date:10/22/2014)... -- Measures taken by Firestone officials at the company,s ... limited the spread of the disease there and could ... Rubber Co. provides health services to about 80,000 employees, ... communities. Between Aug. 1 and Sept. 23, there ... 80,000 people. That incidence rate of 0.09 percent was ...
    (Date:10/20/2014)... Texas (PRWEB) October 20, 2014 The ... the must-have source of thousands of facts, figures and ... countries and 68 medical sector forecast categories the ... with global, regional and national views on the worldwide ... outlook. , The report gives you data for 2010-2019, ...
    Breaking Medicine News(10 mins):Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4
    ... American Heart Association extend their sympathy to the family and friends ... , "It,s a shame when someone his age dies so ... "Although we don,t know all the details of the situation, ... react quickly. Our thoughts and prayers are with the Jackson ...
    ... BOTHELL, Wash., June 25 Verathon(R), the maker of BladderScan(R) ... company,s selection, for the third year in a row, as ... State. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20061011/SFW044LOGO ) , ... for 16th "Best Company To Work For" in the mid-size ...
    ... Association said Thursday that pop singer Michael Jackson,s death at ... arrest, which kills nearly 300,000 Americans each year and is ... cardiac arrest (SCA) is the result of an electrical disruption ... It can strike seemingly healthy individuals without warning, including ...
    ... warns of potential shortage of one pain reliever , THURSDAY, ... and drug ingredients at a Michigan-based manufacturer by the U.S. ... a particular type of pain reliever, the agency said on ... products from plants run by Caraco Pharmaceutical Laboratories Ltd in ...
    ... ... , ... (PRWEB) June 25, 2009 -- Two grocery checkers--a 28-year-old female triathlete and a 53-year-old ... identical. Which employee will return to work sooner? Is there anything you can do ...
    ... Providence Service Corporation (Nasdaq: PRSC ) today ... Inc., have certified the voting results of the Company,s ... preliminary results reported by Providence on June 15, 2009. ... a wide margin, re-elected to the Providence Board of ...
    Cached Medicine News:Health News:American Heart Association Extends Sympathy to Family of Singer Michael Jackson 2Health News:Verathon Recognized, Third Year in a Row, as Outstanding Workplace in Washington State 2Health News:FDA Seizes All Drugs From Generics Maker 2Health News:MDGuidelines Offers New Predictive Modeling Feature 2Health News:MDGuidelines Offers New Predictive Modeling Feature 3Health News:MDGuidelines Offers New Predictive Modeling Feature 4Health News:Providence Service Corporation Announces Certified Voting Results of Annual Meeting of Stockholders 2Health News:Providence Service Corporation Announces Certified Voting Results of Annual Meeting of Stockholders 3
    ... Laparoscopic Instruments incorporate a layered design unique ... and monitored to prevent stray electrosurgical burns ... by insulation failure or capacitive coupling; a ... built into all AEM Instruments provides a ...
    ... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
    ... incorporate a layered design unique in the ... to prevent stray electrosurgical burns along the ... failure or capacitive coupling; a well-documented patient ... all AEM Instruments provides a neutral return ...
    ... incorporate a layered design unique in the ... to prevent stray electrosurgical burns along the ... failure or capacitive coupling; a well-documented patient ... all AEM Instruments provides a neutral return ...
    Medicine Products: